---
title: Third quarter 2020 financial report
description: Gentian Diagnostics AS announces its results for the third quarter of 2020.
---

Moss, 29 October 2020

Gentian Diagnostics AS announces its results for the third quarter of 2020. The highlights include:

- Sales revenue for the first nine months of MNOK 46.1 representing 36 % growth (24 % adjusted for currency effects) compared to the same period last year
- Gentian’s Swedish distribution subsidiary, Gentian Diagnostics AB, has had a sales growth from third party products of 52 % YTD 2020 compared to the same period last year
- Scientific Advisory Board for NT-proBNP (formerly called G-1001) Established
- Study confirms significantly elevated levels of calprotectin in patients with severe COVID-19, which is an opportunity for our GCAL® assay

Please find the report and results presentation here:

[GDAS Interim Report 3Q 2020](https://www.gentian.com/hubfs/GDAS%20Interim%20Report%203Q%202020.pdf)  
[GDAS Interim Presentation 3Q 2020](https://www.gentian.com/hubfs/GDAS%20Interim%20Presentation%203Q%202020.pdf)

 

**For further information, please contact:**

Hilja Ibert CEO, Gentian Diagnostics  
E-mail: [hilja.ibert@gentian.no](mailto:hilja.ibert@gentian.no)  
Cell Phone: +47 919 05 242

Njaal Kind CFO, Gentian Diagnostics  
E-mail: [njaal.kind@gentian.no](mailto:njaal.kind@gentian.no)  
Cell Phone. +47 919 06 525

**MeldingsID: **516640  
**UtstederID:** GENT-ME  
**Marked:** Merkur Market

### You may also read

[Jul 02, 2026 - Ole Sørlie](https://www.gentian.com/investor-relations-stock-information/investors-news/thrid-quarter-2020-financial-report#)

##### [Gentian Diagnostics: Invitation to presentation of second quarter results](https://www.gentian.com/investor-relations-stock-information/investors-news/gentian-diagnostics-invitation-to-presentation-of-second-quarter-results-1)

Gentian Diagnostics ASA will present its second quarter 2026 results on 9 July 2026 at 09.00 CEST. The..

[Read more](https://www.gentian.com/investor-relations-stock-information/investors-news/gentian-diagnostics-invitation-to-presentation-of-second-quarter-results-1)

[Jun 24, 2026 - Ole Sørlie](https://www.gentian.com/investor-relations-stock-information/investors-news/thrid-quarter-2020-financial-report#)

##### [ESSANGE REAGENTS AND GENTIAN DIAGNOSTICS ANNOUNCE COLLABORATION AGREEMENT](https://www.gentian.com/investor-relations-stock-information/investors-news/essange-reagents-and-gentian-diagnostics-announce-collaboration-agreement)

Amsterdam / Moss, 24 June 2026 ESSANGE REAGENTS AND GENTIAN DIAGNOSTICS ANNOUNCE COLLABORATION AGREEMENT..

[Read more](https://www.gentian.com/investor-relations-stock-information/investors-news/essange-reagents-and-gentian-diagnostics-announce-collaboration-agreement)

[May 29, 2026 - Ole Sørlie](https://www.gentian.com/investor-relations-stock-information/investors-news/thrid-quarter-2020-financial-report#)

##### [Mandatory notification of trade](https://www.gentian.com/investor-relations-stock-information/investors-news/mandatory-notification-of-trade-1780055230560)

Moss, 29 May 2026 Gentian Diagnostics ASA ("Gentian") has today been notified that the following transaction..

[Read more](https://www.gentian.com/investor-relations-stock-information/investors-news/mandatory-notification-of-trade-1780055230560)